Skip to main content
NCD 90.2 · version 2

NCD 90.2: Next Generation Sequencing (NGS)

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 90.2

Benefit category
Diagnostic Laboratory Tests, Diagnostic Services in Outpatient Hospital, Diagnostic Tests (other)
Effective date
01/27/2020
Implemented 11/13/2020
Transmittal
Transmittal 10346
Versions published
2
Manual section
90
Genetics, NCD Manual (Pub. 100-03) chapter 1 part 2

TL;DR

NCD 90.2 sets Medicare's national policy for next generation sequencing (ngs) under the benefit category "Diagnostic Laboratory Tests, Diagnostic Services in Outpatient Hospital, Diagnostic Tests (other)", effective 01/27/2020 and implemented 11/13/2020. Effective for services performed on or after March 16, 2018, the Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when… It has been revised 1 time since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. General

Clinical laboratory diagnostic tests can include tests that, for example, predict the risk associated with one or more genetic variations. In addition, in vitro companion diagnostic laboratory tests provide a report of test results of genetic variations and are essential for the safe and effective use of a corresponding therapeutic product. Next Generation Sequencing (NGS) is one technique that can measure one or more genetic variations as a laboratory diagnostic test, such as when used as a companion in vitro diagnostic test.

This National Coverage Determination (NCD) is only applicable to diagnostic lab tests using NGS for somatic (acquired) and germline (inherited) cancer. Medicare Administrative Contractors (MACs) may determine coverage of diagnostic lab tests using NGS for RNA sequencing and protein analysis.

Indications and limitations of coverage

B. Nationally Covered Indications

1. Somatic (Acquired) Cancer

Effective for services performed on or after March 16, 2018, the Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, when ordered by a treating physician, and when all of the following requirements are met:

a. Patient has:

• either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and

• not been previously tested with the same test using NGS for the same cancer genetic content, and

• decided to seek further cancer treatment (e.g., therapeutic chemotherapy).

b. The diagnostic laboratory test using NGS must have:

• Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and,

• an FDA-approved or -cleared indication for use in that patient’s cancer; and,

• results provided to the treating physician for management of the patient using a report template to specify treatment options.

2. Germline (Inherited) Cancer

Effective for services performed on or after January 27, 2020, CMS has determined that NGS as a diagnostic laboratory test is reasonable and necessary and covered nationally for patients with germline (inherited) cancer, when performed in a CLIA-certified laboratory, when ordered by a treating physician and when all of the following requirements are met:

a. Patient has:

• ovarian or breast cancer; and,

• a clinical indication for germline (inherited) testing for hereditary breast or ovarian cancer; and,

• a risk factor for germline (inherited) breast or ovarian cancer; and

• not been previously tested with the same germline test using NGS for the same germline genetic content.

b. The diagnostic laboratory test using NGS must have all of the following:

• FDA-approval or clearance; and,

• results provided to the treating physician for management of the patient using a report template to specify treatment options.

C. Nationally Non-Covered Indications

1. Somatic (Acquired) Cancer

Effective for services performed on or after March 16, 2018, NGS as a diagnostic laboratory test for patients with acquired (somatic) cancer are non-covered if the cancer patient does not meet the criteria noted in section B.1., above.

D. Other

1. Somatic (Acquired) Cancer

Effective for services performed on or after March 16, 2018, Medicare Administrative Contractors (MACs) may determine coverage of NGS as a diagnostic laboratory test for patients with advanced cancer only when the test is performed in a CLIA-certified laboratory, when ordered by a treating physician, and when the patient has:

• either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and,

• not been previously tested with the same test using NGS for the same cancer genetic content, and

• decided to seek further cancer treatment (e.g., therapeutic chemotherapy).

2. Germline (Inherited) Cancer

Effective for services performed on or after January 27, 2020, MACs may determine coverage of NGS as a diagnostic laboratory test for patients with germline (inherited) cancer only when the test is performed in a CLIA-certified laboratory, when ordered by a treating physician, when results are provided to the treating physician for management of the patient and when the patient has:

• any cancer diagnosis; and,

• a clinical indication for germline (inherited) testing of hereditary cancers; and,

• a risk factor for germline (inherited) cancer; and,

• not been previously tested with the same germline test using NGS for the same germline genetic content.

(This NCD last reviewed January 2020)

Text reproduced from the CMS Medicare Coverage Database record for NCD 90.2 version 2. View the original on cms.gov.

Local policies that build on this NCD

41 active Local Coverage Determinations cite NCD 90.2 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

Showing 15 of 41 active LCDs.

How MACs bill NCD 90.2

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 42 current articles in the Medicare Coverage Database name NCD 90.2, 39 of them with a covered ICD-10-CM list, from 6 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A52986: Billing and Coding: Biomarkers for Oncology

Billing and Coding, effective 2025-04-24 · Novitas Solutions, Inc. (04111, 04112, 04211, 04212, 04311, 04312, 04411, 04412, 04911, 07101, 07102, 07201, 07202, 07301, 07302, 12101, 12102, 12201, 12202, 12301, 12302, 12401, 12402, 12501, 12502, 12901) · CMS record

427 covered ICD-10-CM codes in 29 groups; 67 procedure codes: 0018U, 0026U, 0245U, 81120, 81121, 81170, 81175, 81176, 81206, 81207, 81208, 81210 and 55 more. Local policy: L35396 Biomarkers for Oncology. Check a diagnosis for 0018U.

First covered codes: C17.0 Malignant neoplasm of duodenum; C17.1 Malignant neoplasm of jejunum; C17.2 Malignant neoplasm of ileum; C17.3 Meckel's diverticulum, malignant; C17.8 Malignant neoplasm of overlapping sites of small intestine; C17.9 Malignant neoplasm of small intestine, unspecified; …

A54338: Billing and Coding: MolDX: Germline testing for use of PARP inhibitors

Billing and Coding, effective 2025-10-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

68 covered ICD-10-CM codes; 2 procedure codes: 81162, 81479. Local policy: L38966 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 81162.

First covered codes: C25.0 Malignant neoplasm of head of pancreas; C25.1 Malignant neoplasm of body of pancreas; C25.2 Malignant neoplasm of tail of pancreas; C25.3 Malignant neoplasm of pancreatic duct; C25.4 Malignant neoplasm of endocrine pancreas; C25.7 Malignant neoplasm of other parts of pancreas; …

A54689: Billing and Coding: Germline testing for use of PARP inhibitors

Billing and Coding, effective 2023-11-16 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

84 covered ICD-10-CM codes; 2 procedure codes: 81162, 81479. Local policy: L39017 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 81162.

First covered codes: C25.0 Malignant neoplasm of head of pancreas; C25.1 Malignant neoplasm of body of pancreas; C25.2 Malignant neoplasm of tail of pancreas; C25.3 Malignant neoplasm of pancreatic duct; C25.4 Malignant neoplasm of endocrine pancreas; C25.7 Malignant neoplasm of other parts of pancreas; …

A55224: Billing and Coding: MolDX: Germline testing for use of PARP inhibitors

Billing and Coding, effective 2026-06-25 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

68 covered ICD-10-CM codes; 2 procedure codes: 81162, 81479. Local policy: L39040 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 81162.

First covered codes: C25.0 Malignant neoplasm of head of pancreas; C25.1 Malignant neoplasm of body of pancreas; C25.2 Malignant neoplasm of tail of pancreas; C25.3 Malignant neoplasm of pancreatic duct; C25.4 Malignant neoplasm of endocrine pancreas; C25.7 Malignant neoplasm of other parts of pancreas; …

A55294: Billing and Coding: MolDX: Germline testing for use of PARP inhibitors

Billing and Coding, effective 2026-02-19 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

68 covered ICD-10-CM codes; 2 procedure codes: 81162, 81479. Local policy: L38972 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 81162.

First covered codes: C25.0 Malignant neoplasm of head of pancreas; C25.1 Malignant neoplasm of body of pancreas; C25.2 Malignant neoplasm of tail of pancreas; C25.3 Malignant neoplasm of pancreatic duct; C25.4 Malignant neoplasm of endocrine pancreas; C25.7 Malignant neoplasm of other parts of pancreas; …

A56199: Billing and Coding: Molecular Pathology Procedures

Billing and Coding, effective 2026-07-15 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

561 covered ICD-10-CM codes in 31 groups, 9 non-covered; 257 procedure codes: 0027U, 0119U, 81105, 81106, 81107, 81108, 81109, 81110, 81111, 81112, 81120, 81121 and 245 more. Local policy: L35000 Molecular Pathology Procedures. Check a diagnosis for 0027U.

First covered codes: C25.0 Malignant neoplasm of head of pancreas; C25.1 Malignant neoplasm of body of pancreas; C25.2 Malignant neoplasm of tail of pancreas; C25.3 Malignant neoplasm of pancreatic duct; C25.4 Malignant neoplasm of endocrine pancreas; C25.7 Malignant neoplasm of other parts of pancreas; …

A56333: Billing and Coding: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

Billing and Coding, effective 2023-07-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

17 covered ICD-10-CM codes; 2 procedure codes: 0388U, 81479. Local policy: L37921 MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer. Check a diagnosis for 0388U.

First covered codes: C33 Malignant neoplasm of trachea; C34.01 Malignant neoplasm of right main bronchus; C34.02 Malignant neoplasm of left main bronchus; C34.11 Malignant neoplasm of upper lobe, right bronchus or lung; C34.12 Malignant neoplasm of upper lobe, left bronchus or lung; C34.2 Malignant neoplasm of middle lobe, bronchus or lung; …

A56793: Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases

Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

89 covered ICD-10-CM codes in 3 groups; 4 procedure codes: 81450, 81451, 81455, 81456. Local policy: L37606 Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases. Check a diagnosis for 81450.

First covered codes: C92.00 Acute myeloblastic leukemia, not having achieved remission; C92.02 Acute myeloblastic leukemia, in relapse; C92.30 Myeloid sarcoma, not having achieved remission; C92.32 Myeloid sarcoma, in relapse; C92.40 Acute promyelocytic leukemia, not having achieved remission; C92.42 Acute promyelocytic leukemia, in relapse; …

A56867: Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms

Billing and Coding, effective 2026-10-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

675 covered ICD-10-CM codes; 17 procedure codes: 0048U, 0244U, 0250U, 0329U, 0334U, 0379U, 0391U, 0473U, 0543U, 0696U, 81445, 81449 and 5 more. Local policy: L37810 Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms. Check a diagnosis for 0048U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A56924: Billing and Coding: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

Billing and Coding, effective 2023-07-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

17 covered ICD-10-CM codes; 2 procedure codes: 0388U, 81479. Local policy: L37870 MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer. Check a diagnosis for 0388U.

First covered codes: C33 Malignant neoplasm of trachea; C34.01 Malignant neoplasm of right main bronchus; C34.02 Malignant neoplasm of left main bronchus; C34.11 Malignant neoplasm of upper lobe, right bronchus or lung; C34.12 Malignant neoplasm of upper lobe, left bronchus or lung; C34.2 Malignant neoplasm of middle lobe, bronchus or lung; …

A57664: Billing and Coding: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

Billing and Coding, effective 2026-01-22 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

17 covered ICD-10-CM codes; 2 procedure codes: 0388U, 81479. Local policy: L37897 MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer. Check a diagnosis for 0388U.

First covered codes: C33 Malignant neoplasm of trachea; C34.01 Malignant neoplasm of right main bronchus; C34.02 Malignant neoplasm of left main bronchus; C34.11 Malignant neoplasm of upper lobe, right bronchus or lung; C34.12 Malignant neoplasm of upper lobe, left bronchus or lung; C34.2 Malignant neoplasm of middle lobe, bronchus or lung; …

A57831: Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors

Billing and Coding, effective 2026-10-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

622 covered ICD-10-CM codes; 15 procedure codes: 0244U, 0250U, 0329U, 0334U, 0379U, 0543U, 0696U, 81445, 81449, 81455, 81456, 81457 and 3 more. Local policy: L38045 MolDX: Next-Generation Sequencing for Solid Tumors. Check a diagnosis for 0244U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A57837: Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

Billing and Coding, effective 2026-10-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

78 covered ICD-10-CM codes in 2 groups; 6 procedure codes: 81170, 81450, 81451, 81455, 81456, 81479. Local policy: L38047 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies. Check a diagnosis for 81170.

First covered codes: C92.00 Acute myeloblastic leukemia, not having achieved remission; C92.02 Acute myeloblastic leukemia, in relapse; C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse; C92.20 Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission; C92.22 Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse; …

A57858: Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors

Billing and Coding, effective 2026-10-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

622 covered ICD-10-CM codes; 15 procedure codes: 0244U, 0250U, 0329U, 0334U, 0379U, 0543U, 0696U, 81445, 81449, 81455, 81456, 81457 and 3 more. Local policy: L38158 MolDX: Next-Generation Sequencing for Solid Tumors. Check a diagnosis for 0244U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A57867: Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Billing and Coding, effective 2025-07-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

622 covered ICD-10-CM codes; 10 procedure codes: 0179U, 0326U, 0485U, 0487U, 0571U, 81445, 81462, 81463, 81464, 81479. Local policy: L38043 MolDX: Plasma-Based Genomic Profiling in Solid Tumors. Check a diagnosis for 0179U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A57870: Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors

Billing and Coding, effective 2026-09-24 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

582 covered ICD-10-CM codes; 14 procedure codes: 0244U, 0250U, 0329U, 0334U, 0379U, 0543U, 81445, 81449, 81455, 81456, 81457, 81458 and 2 more. Local policy: L38067 MolDX: Next-Generation Sequencing for Solid Tumors. Check a diagnosis for 0244U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.6 Malignant neoplasm of commissure of lip, unspecified; C00.8 Malignant neoplasm of overlapping sites of lip; …

A57873: Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

Billing and Coding, effective 2026-09-24 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

79 covered ICD-10-CM codes in 2 groups; 6 procedure codes: 81170, 81450, 81451, 81455, 81456, 81479. Local policy: L38070 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies. Check a diagnosis for 81170.

First covered codes: C92.00 Acute myeloblastic leukemia, not having achieved remission; C92.02 Acute myeloblastic leukemia, in relapse; C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse; C92.20 Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission; C92.22 Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse; …

A57878: Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

Billing and Coding, effective 2026-10-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

78 covered ICD-10-CM codes in 2 groups; 6 procedure codes: 81170, 81450, 81451, 81455, 81456, 81479. Local policy: L38176 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies. Check a diagnosis for 81170.

First covered codes: C92.00 Acute myeloblastic leukemia, not having achieved remission; C92.02 Acute myeloblastic leukemia, in relapse; C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse; C92.20 Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission; C92.22 Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse; …

A57891: Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

Billing and Coding, effective 2026-10-01 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

78 covered ICD-10-CM codes in 2 groups; 6 procedure codes: 81170, 81450, 81451, 81455, 81456, 81479. Local policy: L38123 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies. Check a diagnosis for 81170.

First covered codes: C92.00 Acute myeloblastic leukemia, not having achieved remission; C92.02 Acute myeloblastic leukemia, in relapse; C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse; C92.20 Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission; C92.22 Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse; …

A57901: Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors

Billing and Coding, effective 2026-10-01 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

622 covered ICD-10-CM codes; 15 procedure codes: 0244U, 0250U, 0329U, 0334U, 0379U, 0543U, 0696U, 81445, 81449, 81455, 81456, 81457 and 3 more. Local policy: L38119 MolDX: Next-Generation Sequencing for Solid Tumors. Check a diagnosis for 0244U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A57917: Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Billing and Coding, effective 2025-07-01 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

622 covered ICD-10-CM codes; 11 procedure codes: 0179U, 0326U, 0485U, 0487U, 0543U, 0571U, 81445, 81462, 81463, 81464, 81479. Local policy: L38065 MolDX: Plasma-Based Genomic Profiling in Solid Tumors. Check a diagnosis for 0179U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58028: Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

Billing and Coding, effective 2024-01-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

9 covered ICD-10-CM codes; 6 procedure codes: 0016M, 81401, 81403, 81404, 81445, 81479. Local policy: L38576 MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer. Check a diagnosis for 0016M.

First covered codes: C67.0 Malignant neoplasm of trigone of bladder; C67.1 Malignant neoplasm of dome of bladder; C67.2 Malignant neoplasm of lateral wall of bladder; C67.3 Malignant neoplasm of anterior wall of bladder; C67.4 Malignant neoplasm of posterior wall of bladder; C67.5 Malignant neoplasm of bladder neck; …

A58065: Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

Billing and Coding, effective 2024-01-01 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

9 covered ICD-10-CM codes; 6 procedure codes: 0016M, 81401, 81403, 81404, 81445, 81479. Local policy: L38586 MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer. Check a diagnosis for 0016M.

First covered codes: C67.0 Malignant neoplasm of trigone of bladder; C67.1 Malignant neoplasm of dome of bladder; C67.2 Malignant neoplasm of lateral wall of bladder; C67.3 Malignant neoplasm of anterior wall of bladder; C67.4 Malignant neoplasm of posterior wall of bladder; C67.5 Malignant neoplasm of bladder neck; …

A58181: Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

Billing and Coding, effective 2026-02-05 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

9 covered ICD-10-CM codes; 6 procedure codes: 0016M, 81401, 81403, 81404, 81445, 81479. Local policy: L38647 MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer. Check a diagnosis for 0016M.

First covered codes: C67.0 Malignant neoplasm of trigone of bladder; C67.1 Malignant neoplasm of dome of bladder; C67.2 Malignant neoplasm of lateral wall of bladder; C67.3 Malignant neoplasm of anterior wall of bladder; C67.4 Malignant neoplasm of posterior wall of bladder; C67.5 Malignant neoplasm of bladder neck; …

A58211: Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

Billing and Coding, effective 2024-01-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

9 covered ICD-10-CM codes; 6 procedure codes: 0016M, 81401, 81403, 81404, 81445, 81479. Local policy: L38684 MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer. Check a diagnosis for 0016M.

First covered codes: C67.0 Malignant neoplasm of trigone of bladder; C67.1 Malignant neoplasm of dome of bladder; C67.2 Malignant neoplasm of lateral wall of bladder; C67.3 Malignant neoplasm of anterior wall of bladder; C67.4 Malignant neoplasm of posterior wall of bladder; C67.5 Malignant neoplasm of bladder neck; …

A58376: Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

Billing and Coding, effective 2026-10-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

681 covered ICD-10-CM codes in 3 groups; 8 procedure codes: 0340U, 0356U, 0422U, 0569U, 0688U, 0689U, 81445, 81479. Local policy: L38779 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0340U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58434: Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

Billing and Coding, effective 2026-03-12 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

681 covered ICD-10-CM codes in 3 groups; 5 procedure codes: 0340U, 0356U, 0422U, 81445, 81479. Local policy: L38822 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0340U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58454: Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

Billing and Coding, effective 2026-10-01 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

681 covered ICD-10-CM codes in 3 groups; 8 procedure codes: 0340U, 0356U, 0422U, 0569U, 0688U, 0689U, 81445, 81479. Local policy: L38814 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0340U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58468: Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

Billing and Coding, effective 2026-10-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

681 covered ICD-10-CM codes in 3 groups; 8 procedure codes: 0340U, 0356U, 0422U, 0569U, 0688U, 0689U, 81445, 81479. Local policy: L38835 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0340U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58652: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Billing and Coding, effective 2026-08-06 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

1,346 covered ICD-10-CM codes in 2 groups; 45 procedure codes: 0101U, 0102U, 0103U, 0129U, 0138U, 81163, 81164, 81165, 81166, 81167, 81201, 81202 and 33 more. Local policy: L38966 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 0101U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58656: Billing and Coding: Thyroid Nodule Molecular Testing

Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

10 covered ICD-10-CM codes; 4 procedure codes: 0018U, 0026U, 81546, 81599. Local policy: L38968 Thyroid Nodule Molecular Testing. Check a diagnosis for 0018U.

First covered codes: D44.0 Neoplasm of uncertain behavior of thyroid gland; D44.9 Neoplasm of uncertain behavior of unspecified endocrine gland; E01.0 Iodine-deficiency related diffuse (endemic) goiter; E01.1 Iodine-deficiency related multinodular (endemic) goiter; E01.2 Iodine-deficiency related (endemic) goiter, unspecified; E04.0 Nontoxic diffuse goiter; …

A58679: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Billing and Coding, effective 2026-08-13 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

1,346 covered ICD-10-CM codes in 2 groups; 45 procedure codes: 0101U, 0102U, 0103U, 0129U, 0138U, 81163, 81164, 81165, 81166, 81167, 81201, 81202 and 33 more. Local policy: L38972 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 0101U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58734: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Billing and Coding, effective 2026-08-06 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

268 covered ICD-10-CM codes; 45 procedure codes: 0101U, 0102U, 0103U, 0129U, 0138U, 81163, 81164, 81165, 81166, 81167, 81201, 81202 and 33 more. Local policy: L39017 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 0101U.

First covered codes: C16.0 Malignant neoplasm of cardia; C16.1 Malignant neoplasm of fundus of stomach; C16.2 Malignant neoplasm of body of stomach; C16.3 Malignant neoplasm of pyloric antrum; C16.4 Malignant neoplasm of pylorus; C16.5 Malignant neoplasm of lesser curvature of stomach, unspecified; …

A58756: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Billing and Coding, effective 2026-08-06 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

1,346 covered ICD-10-CM codes in 2 groups; 45 procedure codes: 0101U, 0102U, 0103U, 0129U, 0138U, 81163, 81164, 81165, 81166, 81167, 81201, 81202 and 33 more. Local policy: L39040 MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer. Check a diagnosis for 0101U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58973: Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Billing and Coding, effective 2026-02-05 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

622 covered ICD-10-CM codes; 10 procedure codes: 0179U, 0326U, 0485U, 0487U, 0571U, 81445, 81462, 81463, 81464, 81479. Local policy: L39230 MolDX: Plasma-Based Genomic Profiling in Solid Tumors. Check a diagnosis for 0179U.

First covered codes: C00.0 Malignant neoplasm of external upper lip; C00.1 Malignant neoplasm of external lower lip; C00.2 Malignant neoplasm of external lip, unspecified; C00.3 Malignant neoplasm of upper lip, inner aspect; C00.4 Malignant neoplasm of lower lip, inner aspect; C00.5 Malignant neoplasm of lip, unspecified, inner aspect; …

A58988: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

Billing and Coding, effective 2025-04-24 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

513 covered ICD-10-CM codes in 4 groups; 17 procedure codes: 0040U, 0364U, 81206, 81207, 81208, 81261, 81263, 81264, 81310, 81315, 81316, 81334 and 5 more. Local policy: L38779 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0040U.

First covered codes: C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site; C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck; C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes; C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes; C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb; C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb; …

A58996: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

Billing and Coding, effective 2026-02-05 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

513 covered ICD-10-CM codes in 4 groups; 17 procedure codes: 0040U, 0364U, 81206, 81207, 81208, 81261, 81263, 81264, 81310, 81315, 81316, 81334 and 5 more. Local policy: L38814 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0040U.

First covered codes: C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site; C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck; C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes; C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes; C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb; C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb; …

A58998: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

Billing and Coding, effective 2025-04-24 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

513 covered ICD-10-CM codes in 4 groups; 17 procedure codes: 0040U, 0364U, 81206, 81207, 81208, 81261, 81263, 81264, 81310, 81315, 81316, 81334 and 5 more. Local policy: L38822 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0040U.

First covered codes: C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site; C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck; C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes; C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes; C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb; C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb; …

A59004: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

Billing and Coding, effective 2025-04-24 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

513 covered ICD-10-CM codes in 4 groups; 17 procedure codes: 0040U, 0364U, 81206, 81207, 81208, 81261, 81263, 81264, 81310, 81315, 81316, 81334 and 5 more. Local policy: L38835 MolDX: Minimal Residual Disease Testing for Cancer. Check a diagnosis for 0040U.

First covered codes: C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site; C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck; C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes; C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes; C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb; C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb; …

A54795: Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Testing in Cancer

Billing and Coding, effective 2024-03-21 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

No covered diagnosis list. Local policy: L38045 MolDX: Next-Generation Sequencing for Solid Tumors, L38047 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies.

A55197: Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Testing in Cancer

Billing and Coding, effective 2024-03-21 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

No covered diagnosis list. Local policy: L38158 MolDX: Next-Generation Sequencing for Solid Tumors, L38176 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies, L36807 MolDX: Molecular Diagnostic Tests (MDT).

A55624: Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Testing in Cancer

Billing and Coding, effective 2026-02-19 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

No covered diagnosis list. Local policy: L38119 MolDX: Next-Generation Sequencing for Solid Tumors, L38123 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies.

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 2 analyses to NCD 90.2, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00450N Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (New, Closed)
  2. CAG-00450R Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (1st Recon, Closed)

Revision history

08/2026 - Transmittal 13752 issued May 26, 2026, is being rescinded and replaced by Transmittal 13910, dated August 14, 2026, to remove business requirement 14464.5, NCD 250.4 Treatment of Actinic Keratosis from the change request. All other information remains the same.( TN 13910 ) (CR14464)

08/2026 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 13906 ) (CR14537)

05/2026 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to NCDs. No policy is being changed as a result of these updates. ( TN 13752 ) (CR14464)

04/2026 - Transmittal 13623 issued February 05, 2026, is being rescinded and replaced by Transmittal 13760, dated April 30, 2026, to remove business requirement 14356.4 and the corresponding spreadsheet for NCD 250.4 Treatment of Actinic Keratosis as this NCD was moved to the October 2026 CR. All other information remains the same. ( TN 13760 ) (CR14356)

02/2026 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 13623 ) (CR14356)

09/2025 - Transmittal 13400 issued September 05, 2025, is being rescinded and replaced by Transmittal 13438, dated September 30, 2025, to add a new attachment to ensure the functionality of the NCD zip URL is working properly and to update the Policy section. All other information remains the same.

The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 coding changes specific to NCDs. ( TN 13438 ) (CR14197)

08/2025 - The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 coding changes specific to NCDs. ( TN 13375 ) (CR14197)

03/2025 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 13097 ) (CR13939)

05/2024 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 12626 ) (CR13596)

01/2024 - Transmittal 12355 issued November 09, 2023, is being rescinded and replaced by Transmittal 12444, January 4, 2024 to add clarifying verbiage to NCD 90.2, business requirement 13278.2, and related edits to NCD 90.2, Next Generation Sequencing, attached spreadsheet. All other information remains the same. ( TN 12444 ) (CR13278)

01/2024 - Transmittal 12350 issued November 03, 2023, is being rescinded and replaced by Transmittal 12440 dated January 3, 2024, to make changes to NCD 90.2, Next Generation Sequencing, spreadsheet to align with revisions being made to CR 13278. All other information remains the same. ( TN 12440 ) (CR13391)

11/2023 - The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received. ( TN 12355 ) (CR13278)

11/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates.( TN 12350 ) (CR13391)

10/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 12319 ) (CR13391)

08/2023 - The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. ( TN 12184 ) (CR13278)

05/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determination (NCDs). No policy is being changed as a result of these updates. ( TN 12017 ) (CR13166)

06/2022 - Transmittal 11055, dated October 21, 2021, is being rescinded and replaced by Transmittal 11461, dated, June 21, 2022 to revise BR 12483.1 and corresponding spreadsheet to align with changes made in previous CR 12124 and later CR 12705. All other information remains the same. ( TN 11461 ) (CR12483)

06/2022 - Transmittal 11400, dated May 4, 2022, is being rescinded and replaced by Transmittal 11460, dated, June 17, 2022, to update NCD 90.2, NGS, spreadsheet to conform with changes in CR 12124, and change the implementation date for all business requirements except 12705.6 to 30 days from issuance of this correction. All other information remains the same.( TN 11460 ) (CR12705)

06/2022 - Transmittal 10832, dated June 2, 2021, is being rescinded and replaced by Transmittal 11453, dated, June 10, 2022, to revise NCD 90.2, NGS, revises business requirement 12124.2 and 12124.2.1 and its associated spreadsheet of coding by retainining all ICD-10 NOC diagnosis codes proposed for deletion effective July 1, 2022. ( TN 11453 ) (CR12124)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 90.2

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 90.2

What does NCD 90.2 cover?

Effective for services performed on or after March 16, 2018, the Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, when ordered by a treating physician, and when all of the following… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 90.2 take effect?

The current version (2) is effective 01/27/2020, implemented 11/13/2020, published in transmittal 10346. CMS lists 2 versions of this NCD.

Does a Local Coverage Determination override NCD 90.2?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.